Pretreatment Axillary Nodal Volume as a Prognostic Factor for Breast Cancer

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Breast Journal Pub Date : 2025-04-23 DOI:10.1155/tbj/1823771

Yuri Jeong, Jung Hoon Kim, Su Ssan Kim, Jinhong Jung, Ji Hyeon Joo, Hwa Jung Kim, Hak Hee Kim, Joo Hee Cha, Hee Jung Shin, Seung Do Ahn

{"title":"Pretreatment Axillary Nodal Volume as a Prognostic Factor for Breast Cancer","authors":"Yuri Jeong, Jung Hoon Kim, Su Ssan Kim, Jinhong Jung, Ji Hyeon Joo, Hwa Jung Kim, Hak Hee Kim, Joo Hee Cha, Hee Jung Shin, Seung Do Ahn","doi":"10.1155/tbj/1823771","DOIUrl":null,"url":null,"abstract":"<div>\n Background and Objectives: We evaluated the prognostic value of pretreatment axillary nodal volume in breast cancer patients treated with neoadjuvant systemic therapy.\n Methods: We retrospectively reviewed 302 breast cancer patients with biopsy-proven axillary LN involvement who received neoadjuvant systemic therapy. Axillary nodal volumes were obtained from pretreatment magnetic resonance imaging. Univariate and multivariate analyses for disease-free survival (DFS) and overall survival (OS) rates were conducted.\n Results: The median follow-up period was 57.0 months, and 5-year DFS and OS rates were 81.6% and 91.9%, respectively. Pretreatment axillary nodal volume ranged from 0.2 mL to 134.2 mL, and the first tertile (2.6 mL) and fifth quintile (12.0 mL) were chosen as the optimal cutoff points for survival outcomes. In the multivariate analysis, nodal volume (< 2.6 mL vs. 2.6–12.0 mL vs. ≥ 12.0 mL) was a significant prognostic factor for DFS (5-year DFS, 90.1% vs. 79.6% vs. 72.2%) and OS (5-year OS, 97.9% vs. 90.9% vs. 84.2%), whereas the N stage was not.\n Conclusions: In breast cancer patients treated with neoadjuvant systemic therapy, larger pretreatment axillary nodal volume was associated with poor survival outcomes.\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/1823771","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/tbj/1823771","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Objectives: We evaluated the prognostic value of pretreatment axillary nodal volume in breast cancer patients treated with neoadjuvant systemic therapy.

Methods: We retrospectively reviewed 302 breast cancer patients with biopsy-proven axillary LN involvement who received neoadjuvant systemic therapy. Axillary nodal volumes were obtained from pretreatment magnetic resonance imaging. Univariate and multivariate analyses for disease-free survival (DFS) and overall survival (OS) rates were conducted.

Results: The median follow-up period was 57.0 months, and 5-year DFS and OS rates were 81.6% and 91.9%, respectively. Pretreatment axillary nodal volume ranged from 0.2 mL to 134.2 mL, and the first tertile (2.6 mL) and fifth quintile (12.0 mL) were chosen as the optimal cutoff points for survival outcomes. In the multivariate analysis, nodal volume (< 2.6 mL vs. 2.6–12.0 mL vs. ≥ 12.0 mL) was a significant prognostic factor for DFS (5-year DFS, 90.1% vs. 79.6% vs. 72.2%) and OS (5-year OS, 97.9% vs. 90.9% vs. 84.2%), whereas the N stage was not.

Conclusions: In breast cancer patients treated with neoadjuvant systemic therapy, larger pretreatment axillary nodal volume was associated with poor survival outcomes.

Abstract Image

查看原文本刊更多论文

腋窝淋巴结体积预处理作为乳腺癌的预后因素

背景和目的：我们评估腋窝淋巴结体积预处理在乳腺癌患者接受新辅助全身治疗中的预后价值。方法：我们回顾性分析了302例活检证实腋窝淋巴结受累并接受新辅助全身治疗的乳腺癌患者。腋窝淋巴结体积通过预处理磁共振成像获得。对无病生存（DFS）和总生存（OS）率进行单因素和多因素分析。结果：中位随访期为57.0个月，5年DFS和OS率分别为81.6%和91.9%。预处理腋窝淋巴结体积范围为0.2 mL至134.2 mL，选择第一分位数（2.6 mL）和第五分位数（12.0 mL）作为生存结果的最佳截止点。在多变量分析中，淋巴结体积(<；2.6 mL vs. 2.6 - 12.0 mL vs.≥12.0 mL)是DFS（5年DFS， 90.1% vs. 79.6% vs. 72.2%）和OS（5年OS， 97.9% vs. 90.9% vs. 84.2%）的重要预后因素，而N期则不是。结论：在接受新辅助全身治疗的乳腺癌患者中，较大的预处理腋窝淋巴结体积与较差的生存结果相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.